Michael Aberman joins Regeneron
Former Wall Street analyst joins firm at pivotal time
Prior to joining Regeneron, Aberman spent six years as a Wall Street research analyst covering the biotechnology industry. Most recently, he was director and senior biotechnology analyst at Credit Suisse and before that, vice president and biotech analyst at Morgan Stanley. Before moving to Wall Street, Aberman was director of business development at Antigenics, an oncology-focused biotechnology company.
‘I am very excited to be joining Regeneron at a pivotal time in its history,’ said Aberman. ‘2010 will bring results from multiple Phase III trials in gout, age-related macular degeneration, and cancer. In addition, the expanded collaboration with Sanofi-Aventis positions Regeneron to capitalise on its capabilities to build a robust pipeline of antibody-based product candidates over the coming years.’
You may also like
Regulatory
Sanofi and Regeneron announce Marketing Authorisation Application for Dupixent (dupilumab) accepted for review by the EMA
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) for Dupixent® (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy
Sustainability
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security